Background: Gap junctional intercellular communication (GJIC) is a mechanism for direct cell-to-cell signalling and is mediated by gap junctions, which consist of transmembrane proteins called connexins (Cxs). Human colorectal epithelial cells express Cx32 and Cx43. Methods: Tissue samples (152 from colorectal cancer and 75 from adenoma) were investigated by immunohistochemistry, using the antibody for Cx26. Moreover, Cx26 was assessed in normal epithelium of the colon and rectum, adjacent to colorectal cancer. Results: In normal epithelium and adenomas, intercellular, punctate staining for Cx26 was observed. In adenomas with severe dysplasia, focally decreased expression of Cx26 was observed. Among 152 colorectal cancers, 55.9% classified only as adenocarcinoma stained positive for Cx26, but mainly cytoplasmic staining was found. We observed a positive correlation between Cx26 expression and tumor G2 grade (p < 0.005). The expression of Cx26 did not correlate with age, sex of patients, tumor localization, lymph node status or tumor size. Conclusions: Our results show that during colorectal carcinogenesis, loss of normal intercellular Cx expression occurs. Furthermore, the cytoplasmic presence of Cx26 could indicate a different role of Cx26 in neoplastic cells than participation in GJIC.

1.
Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, Guldenagel M, Deutsch U, Sohl G: Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 2002;383:725–737.
2.
Krutovskikh VA, Piccoli C, Yamasaki H: Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 2002;21:1989–1999.
3.
Trosko JE, Chang CC: Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer. Mutat Res 2001;480–481:219–229.
4.
Wilgenbus KK, Kirkpatrick CJ, Knuechel R, Willecke K, Traub O: Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer 1992;51:522–529.
5.
Trosko JE, Ruch RJ: Cell-cell communication in carcinogenesis. Front Biosci 1998;3:208–236.
6.
Yamasaki H, Naus CC: Role of connexin genes in growth control. Carcinogenesis 1996;17:1199–1213.
7.
Naus CCG: Gap junctions and tumour progression. Can J Physiol Pharmacol 2002;80:136–141.
8.
Huang RP, Fan Y, Hossain MZ, Peng A, Zeng ZL, Boynton AL: Reversion of the neoplastic phenotype of human glioblastoma cells by connexin43 (Cx43). Cancer Res 1998;58:5089–5096.
9.
Giepmans BN, Moolenaar WH: The gap junction protein connexin43 interacts with the second PDZ domain of the zona occludens-1 protein. Curr Biol 1998;8:931–934.
10.
Loo LW, Kanemitsu MY, Lau AF: In vivo association of pp60v-src and the gap-junction protein connexin43 in v-src-transformed fibroblasts. Mol Carcinog 1999;25:187–195.
11.
Dubina MV, Iatckii NA, Popov DE, Vasil’ev SV, Krutovskikh VA: Connexin43, but not connexin32, is mutated at advanced stages of human sporadic colon cancer. Oncogene 2002;21:4992–4996.
12.
Koda M, Sulkowski S, Garofalo C, Kanczuga-Koda L, Sulkowska M: Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: Correlations with estrogen receptors alpha and beta. Horm Metab Res 2003;35:794–801.
13.
Falk MM: Biosynthesis and structural composition of gap junction intercellular membrane channels. Eur J Cell Biol 2000;79:564–574.
14.
Evans WH, Martin PE: Gap junctions: Structure and function (review). Mol Membr Biol 2002;19:121–136.
15.
Jamieson S, Going JJ, D’Arcy R, George WD: Expression of gap junction proteins connexin26 and connexin43 in normal human breast and in breast tumours. J Pathol 1998;184:37–43.
16.
Laird DW, Fistouris P, Batist G, Alpert L, Huynh HT, Carystinos GD, Alaoui-Jamali MA: Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res 1999;59:4104–4110.
17.
Umhauer S, Ruch RJ, Fanning J: Gap junctional intercellular communication and connexin43 expression in ovarian carcinoma. Am J Obstet Gynecol 2000;182:999–1000.
18.
Gee J, Tanaka M, Grossman HB: Connexin26 is abnormally expressed in bladder cancer. J Urol 2003;169:1135–1137.
19.
Krutovskikh VA, Troyanovsky SM, Piccoli C, Tsuda H, Asamoto M, Yamasaki H: Differential effect of subcellular localization of communication impairing gap junction protein connexin43 on tumor cell growth in vivo. Oncogene 2000;19:505–513.
20.
Defamie N, Mograbi B, Roger C, Cronier L, Malassine A, Brucker-Davis F, Fenichel P, Segretain D, Pointis G: Disruption of gap junctional intercellular communication by lindane is associated with aberrant localization of connexin43 and zonula occludens-1 in 42GPA9 Sertoli cells. Carcinogenesis 2001;22:1537–1542.
21.
Olbina G, Eckhart W: Mutations in the second extracellular region of connexin43 prevent localization to the plasma membrane, but do not affect its ability to suppress cell growth. Mol Cancer Res 2003;1:690–700.
22.
Ito A, Katoh F, Kataoka TR, Okada M, Tsubota N, Asada H, Yoshikawa K, Maeda S, Kitamura Y, Yamasaki H, Nojima H: A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J Clin Invest 2000;105:1189–1197.
23.
Saunders MM, Seraj MJ, Li Z, Zhou Z, Winter CR, Welch DR, Donahue HJ: Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001;61:1765–1767.
24.
King TJ, Fukushima LH, Hieber AD, Shimabukuro KA, Sakr WA, Bertram JS: Reduced levels of connexin43 in cervical dysplasia: Inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. Carcinogenesis 2000;21:1097–1109.
25.
Habermann H, Ray V, Habermann W, Prins GS: Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 2001;166:2267–2272.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.